Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 9/20 | 0.56 |
| ▸ | KDR | P35968 | 7/20 | 0.56 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | ITK | Q08881 | 9/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29695771 | 0.83 | RET (0.62) | RETKDR | |
| SCHEMBL24785488 | 0.83 | RET (0.62) | RETKDR | |
| SCHEMBL16665690 | 0.77 | PIK3CD (0.39) | RETKDRSRCABL1ITK | |
| SCHEMBL23917253 | 0.77 | PIK3CD (0.39) | RETKDRSRCABL1ITK | |
| SCHEMBL23917557 | 0.76 | RET (0.39) | RETKDRSRCABL1 | |
| SCHEMBL16665832 | 0.76 | RET (0.39) | RETKDRSRCABL1 | |
| SCHEMBL16665728 | 0.76 | RET (0.56) | RETKDRSRCABL1ITK | |
| SCHEMBL3605078 | 0.75 | PIK3CD (0.61) | KDRSRCABL1 | |
| SCHEMBL13717957 | 0.75 | PIK3CD (0.58) | KDRSRCABL1 | |
| SCHEMBL19299621 | 0.74 | RET (0.73) | RETKDRSRCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3442980-B1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-06-09 | — | — | EP | disclosed |
| WO-2017178844-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | RET 753/4885KDR 858/4885SRC 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.